After Merck success, work goes on with other Ebola vaccines
July 31, 2015 at 11:29 AM EDT
LONDON, July 31 (Reuters) - Scientists and drug companies will continue to research the potential of alternative Ebola vaccines, despite a shot from Merck and NewLink Genetics proving 100 percent effective in a trial in Guinea.